Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;21(1):3-17.
doi: 10.1007/s12094-018-1978-1. Epub 2018 Nov 17.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

M Majem  1 , O Juan  2 , A Insa  3 , N Reguart  4 , J M Trigo  5 , E Carcereny  6 , R García-Campelo  7 , Y García  8 , M Guirado  9 , M Provencio  10
Affiliations

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

M Majem et al. Clin Transl Oncol. 2019 Jan.

Abstract

Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment attains greater value.

Keywords: Chemotherapy; Immunotherapy; NSCLC; Radiotherapy; Targeted therapies.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

MM reports personal fees from AstraZeneca, Roche, Lilly, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Novartis, Tesaro, outside the submitted work. OJ reports grants from Astra Zeneca and personal fees from Astra Zeneca, BMS, MSD, ROCHE, Boehringer Ingelheim, Lilly outside the submitted work. MP reports grants from BMS, Roche and personal fees from BMS, MSD, ROCHE, Pierre Fabre, Novartis; Takeda, Lilly, Pfizer outside the submitted work. NR reports advisory Board/Consultancy/Speaker honoraria from MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Guardant Health, Pfizer, Abbie, Ipsen, Novartis, Astra-Zeneca, Lilly, Takeda outside the submitted work; Research Funding from Pfizer, NanoString Technology, and Institutional financial interests related to clinical trials and patient recruitment. GC reports non-financial support from Millennium Pharmaceuticals, Inc., during the conduct of the study; personal fees from ARIAD, AstraZeneca, Roche, Pfizer, BMS, Boehringer Ingelheim, MSD outside the submitted work. YG reports personal fees from Roche, Boehriger-ingelheim, Lilly, MSD, Pfizer, BMS outside the submitted work. JMT reports personal fees from Roche, Boehriger-ingelheim, BMS, Astra Zeneca, MerckSerono outside the submitted work. AI, EC, MG, have not reported any potential conflicts of interest.

Ethical approval

The current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

No informed consent was necessary for this guideline.

Figures

Fig. 1
Fig. 1
Treatment algorithm for Stage III
Fig. 2
Fig. 2
Treatment algorithm for Stage IV with no targetable alterations
Fig. 3
Fig. 3
Treatment algorithm for Stage IV with known targetable drivers
See this image and copyright information in PMC

References

    1. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi: 10.1097/JTO.0000000000000630. - DOI - PubMed
    1. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. J Mol Diagn. 2018;20(2):129–159. doi: 10.1016/j.jmoldx.2017.11.004. - DOI - PubMed
    1. Felip E, Concha A, de Castro J, Gomez-Roman J, Garrido P, Ramirez J, et al. Biomarker testing in advanced non-small-cell lung cancer: a national consensus of the spanish society of pathology and the spanish society of medical oncology. Clin Transl Oncol. 2015;17(2):103–112. doi: 10.1007/s12094-014-1248-9. - DOI - PubMed
    1. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v1–v27. doi: 10.1093/annonc/mdw326. - DOI - PubMed
    1. Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathozlogists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. J Clin Oncol. 2018;36(9):911–919. doi: 10.1200/JCO.2017.76.7293. - DOI - PubMed